http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020121765-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_135518e322e9ff137f59beb64470dfce |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0029 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y301-03001 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-465 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
| filingDate | 2017-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_568e29e446287cb894a764c9029aa0ed http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf9c6e3207f26670f6b6d78ed8e475d2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7bf7901e7bb4b5e9f8e7c4ffb3b35b95 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39d9671fb664330a34bc0f4e5766ce13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_abca22b61ea43e7702879d75459c7d64 |
| publicationDate | 2020-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2020121765-A1 |
| titleOfInvention | Composition Comprising Alkaline Phosphatase for Use in the Treatment of Arthritides |
| abstract | Present invention relates to a composition for use in the treatment of arthritides. Alkaline phosphatase (AP), an ectophosphatase with an anti-inflammatory and barrier protecting mechanism of action shows potent anti-rheumatoid arthritis (anti-RA) efficacy in a rat model for arthritis. In this model RA was induced by subcutaneous immunization with a mixture of methylated bovine serum albumin (mBSA), CFA (complete Freund's adjuvant antigen) and CBP (custom Bordetella pertussis antigen) and intra-articular injections of mBSA. Results were comparable with those obtained for MTX, the drug reference compound for the treatment of RA. Both knee swelling over time and the number of invading macrophages were found to be reduced with AP treatment, either applied in prophylactic treatment or therapeutic treatment, and comparable to the MTX effects. AP was found effective both as prophylactic, and as therapeutic intervention. Altogether, ectophosphatase intervention by AP fulfills a novel and unmet niche in RA treatment by combining different, yet synergistic mode of actions with MTX. |
| priorityDate | 2017-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 224.